The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome;Trombotik anjiyopati ve antifosfolipid sendromunda kompleman İnhibisyonunun rolü

Turkish Journal of Hematology

Volumn 33, Issue 1, 2016, Pages 1-7

  Erkan, Doruk ^a   Salmon, Jane E ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Antiphospholipid syndrome; Complement inhibition; Eculizumab; Thrombotic angiopathy

Indexed keywords

ECULIZUMAB; PHOSPHOLIPID ANTIBODY; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL (TOPIC); COMPLEMENT INHIBITION; DISEASE COURSE; ENDOTHELIUM CELL; GENE MUTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; MUTATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLACENTA INSUFFICIENCY; REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE; ABORTION, HABITUAL; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLEMENT CLASSICAL PATHWAY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; MALE; MOUSE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PHYSIOLOGY; PLACENTAL INSUFFICIENCY; PREGNANCY; THROMBOPHILIA; THROMBOTIC MICROANGIOPATHIES;

ABORTION, HABITUAL; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIALS AS TOPIC; COMPLEMENT C5A; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, CLASSICAL; DISEASE MODELS, ANIMAL; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MICE; MULTICENTER STUDIES AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; PLACENTAL INSUFFICIENCY; PREGNANCY; RECEPTOR, ANAPHYLATOXIN C5A; THROMBOPHILIA; THROMBOTIC MICROANGIOPATHIES;

EID: 84958779556     PISSN: 13007777     EISSN: 13085263     Source Type: Journal    
DOI: 10.4274/tjh.2015.0197     Document Type: Review

References (55)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
2. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-1226
3. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-1243
4. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181
5. Lynch AM, Salmon JE. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010;31:561-567
6. Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 2013;64:307-324
7. Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008;223:300-316
8. Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens 2010;19:242-247
9. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:1847-1848
10. Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskeletal Dis 2013;5:305-314
11. Parker JC. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012;19:141-148
12. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000;287:498-501
13. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-1243
14. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006;203:2165-2175
15. Gelber SE, Brent E, Redecha P, Perino G, Tomlinson S, Davisson RL, Salmon JE. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol 2015;195:1129-1138
16. Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, Salmon JE, Holers VM. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008;198:385. 1-9
17. Rampersad R, Barton A, Sadovsky Y, Nelson DM. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 2008;29:855-861
18. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-559
19. Tsai E, Chapin J, Laurence JC, Tsai HM. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013;162:558-559
20. Shoenfeld Y. Etiology and pathogenetic mechanisms of the antiphospholipid syndrome unraveled. Trends Immunol 2003;24:2-4
21. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 2007;9:212-218
22. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832
23. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737-1740
24. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033-1044
25. Erkan D, Salmon J, Lockshin MD. Antiphospholipid syndrome. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, Odell JR (eds). Kelley’s Textbook of Rheumatology, 9th ed. Philadelphia, Elsevier Saunders, 2013
26. Alpert D, Mandl LA, Erkan D, Yin W, Peersche EI, Salmon JE. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008;67:395-401
27. D’Cruz D. Renal manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2009;11:52-60
28. Gigante A, Gasperini ML, Cianci R, Barbano B, Giannakakis K, Di Donato D, Fuiano G, Amoroso A. Antiphospholipid antibodies and renal involvement. Am J Nephrol 2009;30:405-412
29. Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noël LH, Dragon-Durey MA, Snanoudj R, Friedlander G, Halbwachs-Mecarelli L, Legendre C, Terzi F. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303-312
30. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654
31. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2002
32. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-2219
33. Bulla R, Bossi F, Fischetti F, De Seta F, Tedesco F. The complement system at the fetomaternal interface. Chem Immunol Allergy 2005;89:149-157
34. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109:422-430
35. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010;47:2170-2175
36. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD. A novel C5a receptor-tissue factor crosstalk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006;177:4794-4802
37. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007;110:2423-2431
38. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-2124
39. Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost 2009:101:271-278
40. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167. 1-5
41. Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest 2012;42:1126-1135
42. Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev 2014;14:446-471
43. Devreese K, Hoylaerts MF. Is there an association between complement activation and antiphospholipid antibody related thrombosis? Thromb Haemost 2010;104:1279-1281
44. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362:1744-1745
45. Velik-Salchner C, Lederer W, Wiedermann F. Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation. Lupus 2011;20:772
46. Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011;11:2523-2527
47. Darnige L, Peffault de Latour R, Zemori L, Socié G, Fischer AM, Helley D; French Society of Haematology. Antiphospholipid antibodies in patients with paroxysmal nocturnal haemoglobinuria receiving eculizumab. Br J Haematol 2011;153:789-791
48. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012;64:2719-2723
49. Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noël LH, GuilbeauFrugier C, Sberro-Soussan R, Del Bello A, Martinez F, Zuber J, Rostaing L, Legendre C. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013;13:2179-2185
50. Mushin SA, Khianey R, Erkan D. Discordant aPTT and anti-FXa values in a catastrophic antiphospholipid syndrome patient receiving intravenous unfractionated heparin. In: 14th International Congress on Antiphospholipid Antibodies Abstract Book, 2013;1:14-76 (abstract)
51. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: Task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-696
52. Bakhtar O, Thajudeen B, Braunhut BL, Yost SE, Bracamonte ER, Sussman AN, Kaplan B. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 2014;98:17-18
53. Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, Singer AL, Carter-Monroe N, Nazarian SM, Segev DL, Streiff MB, Montgomery RA. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014;14:459-465
54. Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-yearold female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 2014;2014:704-371
55. Zapantis E, Furie R, Horowitz D. Eculizumab in antiphospholipid antibody syndrome. Arthritis Rheum 2014;66(Suppl):6(abstract).